Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice

Abstract: Little is known about the dosing and tolerability of sacubitril/valsartan (LCZ696; Entresto, Quebec, Canada) in a nonclinical trial population. This study was conducted to evaluate the use and tolerability of sacubitril/valsartan in patients followed at a multidisciplinary heart failure (HF) clinic. We performed a retrospective chart review of 126 patients with HF, initiated on sacubitril/valsartan, and seen at a specialty HF clinic between August 1, 2015, and August 1, 2017. We defined the target dose of sacubitril/valsartan as 200 mg twice a day. At baseline, median age was 67 years, 77% were men, median ejection fraction was 29%, and 86.5% of patients had symptoms of New York Heart Association class ≥II. Within 6 months of being transitioned onto sacubitril/valsartan therapy, 27.2% achieved the target dose of 200 mg twice a day, 40.8% achieved the target dose of 100 mg twice a day, and 32.0% achieved the target dose of 50 mg twice a day. The main reasons for not achieving target dose within 6 months included slower uptitration of therapy than in the trial (n = 41, 54.7%), a decrease in systolic blood pressure (n = 19, 25.3%), not completing blood work (n = 3, 4%), and patient noncompliance (n = 3, 4%). Overall, achievement of sacubitril/valsartan target doses was modest in a tertiary HF clinic, limited by various factors such as side effects and patients' medication noncompliance. Implementation of patient and clinician support pathways may improve uptake, uptitration, and maintenance of evidence-based doses in clinical practice.

[1]  S. Stemkowski,et al.  An Early View of Real-World Patient Response to Sacubitril/Valsartan: A Retrospective Study of Patients with Heart Failure with Reduced Ejection Fraction , 2018, Advances in Therapy.

[2]  P. Martens,et al.  Insights into implementation of sacubitril/valsartan into clinical practice , 2018, ESC heart failure.

[3]  M. Lelonek,et al.  Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland. , 2018, Kardiologia polska.

[4]  R. McKelvie,et al.  2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. , 2017, The Canadian journal of cardiology.

[5]  M. Barrett,et al.  14 The use of sacubitril/valsartan: a real world experience in a high volume specialist heart failure service , 2017, Heart.

[6]  L. Dyall,et al.  13 Keeping up the beat: a quality improvement project on heart failure monitoring & management , 2017 .

[7]  Emily C. O'Brien,et al.  Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF). , 2017, JACC. Heart failure.

[8]  F. McAlister,et al.  The current and future financial burden of hospital admissions for heart failure in Canada: a cost analysis. , 2016, CMAJ open.

[9]  R. Wachter,et al.  Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double‐blind, randomized comparison of two uptitration regimens , 2016, European journal of heart failure.

[10]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[11]  Karl Swedberg,et al.  Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. , 2013, European heart journal.

[12]  Paul A. Harris,et al.  Procurement of shared data instruments for Research Electronic Data Capture (REDCap) , 2013, J. Biomed. Informatics.

[13]  G. Fonarow,et al.  Epidemiology and risk profile of heart failure , 2011, Nature Reviews Cardiology.

[14]  F. McAlister Cardiac resynchronization therapy for heart failure: a hammer in search of nails. , 2008, Circulation.

[15]  R. Stafford,et al.  Off-label prescribing among office-based physicians. , 2006, Archives of internal medicine.

[16]  P. Armstrong,et al.  The Use of -Blockers in a Tertiary Care Heart Failure Clinic , 2004 .

[17]  M. Wiktorowicz,et al.  Emergent Patterns in the Regulation of Pharmaceuticals: Institutions and Interests in the United States, Canada, Britain and France , 2003, Journal of health politics, policy and law.

[18]  Harlan M Krumholz,et al.  Representation of the elderly, women, and minorities in heart failure clinical trials. , 2002, Archives of internal medicine.